Role of advanced glycation end products (AGEs) in osteoporosis in diabetes

Current Drug Targets

Volumn 12, Issue 14, 2011, Pages 2096-2102

  Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Osteoporosis; Oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CASPASE 8; CASPASE 9; ESTRADIOL; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCALCIN; PARATHYROID HORMONE; PENTOSIDINE; RALOXIFENE; REACTIVE OXYGEN METABOLITE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

APOPTOSIS; BLOOD LEVEL; BONE DENSITY; BONE FRAGILITY; CELL DIFFERENTIATION; CELL PROLIFERATION; DIABETES MELLITUS; ESTRADIOL BLOOD LEVEL; GLYCATION; HORMONAL THERAPY; HUMAN; HYPERHOMOCYSTEINEMIA; MESENCHYMAL STEM CELL; MOLECULAR WEIGHT; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OXIDATIVE STRESS; POSTMENOPAUSE; RABBIT; REVIEW; RHEUMATOID ARTHRITIS; URINE LEVEL;

ANIMALS; APOPTOSIS; BONE DENSITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MESENCHYMAL STEM CELLS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84855833476     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798829456     Document Type: Review

References (78)

1. Osteoporosis Prevention, Diagnosis and Therapy: NIH Consensus Statement 2000; 17: 1-36. http://consensus.nih.gov/2000/ 2000Osteoporosis111html.htm
2. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-87.
3. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 2010; 20: 683-90.
4. Kurra S, Siris E. Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures. Diabetes Metab Res Rev 2011; doi: 10.1002/dmrr.1197.
5. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 2007; 18: 427-44.
6. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007; 22: 1317-28.
7. Pietschmann P, Patsch JM, Schernthaner G. Diabetes and bone. Horm Metab Res 2010; 42: 763-8.
8. Isidro ML, Ruano B. Bone disease in diabetes. Curr Diabetes Rev 2010; 6: 144-55.
9. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16: 1713-20.
10. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
11. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
12. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
13. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11654-60.
14. Persy V, D'Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 2009; 15: 405-16.
15. Naves M, Rodríguez-García M, Díaz-López JB, Gómez-Alonso C, Cannata-Andía JB. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008; 19: 1161-6.
16. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011; 46: 217-24.
17. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002; 54: 1615-25.
18. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600.
19. Yamagishi S, Matsui T. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr Drug Targets 2010; 11: 875-81.
20. Suga T, Iso T, Shimizu T, et al. Activation of Receptor for Advanced Glycation End Products Induces Osteogenic Differentiation of Vascular Smooth Muscle Cells. J Atheroscler Thromb 2011 (in press)
21. Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun 1999; 258: 353-7.
22. Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005; 65: 1013-5.
23. Hein GE. Glycation endproducts in osteoporosis--is there a pathophysiologic importance? Clin Chim Acta 2006; 371: 32-6.
24. Odetti P, Rossi S, Monacelli F, et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 2005; 1043: 710-7.
25. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010; 21: 195-214.
26. Mercer N, Ahmed H, Etcheverry SB, Vasta GR, Cortizo AM. Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 2007; 306: 87-94.
27. Schurman L, McCarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008; 116: 333-40.
28. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996; 11: 931-7.
29. Katayama Y, Celic S, Nagata N, Martin TJ, Findlay DM. Nonenzymatic glycation of type I collagen modifies interaction with UMR 201-10B preosteoblastic cells. Bone 1997; 21: 237-42.
30. McCarthy AD, Etcheverry SB, Bruzzone L, et al. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2001; 2: 16.
31. McCarthy AD, Uemura T, Etcheverry SB, Cortizo AM. Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol 2004; 36: 840-8.
32. Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40: 345-53.
33. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 2008; 1126: 166-72.
34. McCarthy AD, Cortizo AM, Giménez Segura G, Bruzzone L, Etcheverry SB. Non-enzymatic glycosylation of alkaline phosphatase alters its biological properties. Mol Cell Biochem 1998; 181: 63-9.
35. Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997; 8: 260-70.
36. Dong XN, Qin A, Xu J, Wang X. In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption. Bone 2011 (in press)
37. Valcourt U, Merle B, Gineyts E, et al. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 2007; 282: 5691-703.
38. Zhou Z, Immel D, Xi CX, et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203: 1067-80.
39. Ding KH, Wang ZZ, Hamrick MW, et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 2006; 340: 1091-7.
40. Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 2007; 113: 154-61.
41. Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr 2009; 19: 61-72.
42. Zhou Z, Han JY, Xi CX, et al. HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J Bone Miner Res 2008; 23: 1084-96.
43. Yang K, Wang XQ, He YS, et al. Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol 2010; 9: 66.
44. Stolzing A, Sellers D, Llewelyn O, Scutt A. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 2010; 191: 453-65.
45. Kume S, Kato S, Yamagishi S, et al. Advanced glycation endproducts attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20: 1647-58.
46. Tang SY, Vashishth D. Non-enzymatic glycation alters microdamage formation in human cancellous bone. Bone 2010; 46: 148-54.
47. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17: 1514-23.
48. Tang SY, Vashishth D. The relative contributions of non-enzymatic glycation and cortical porosity on the fracture toughness of aging bone. J Biomech 2011; 44: 330-6.
49. Viguet-Carrin S, Roux JP, Arlot ME, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 2006; 39: 1073-9.
50. Hein G, Weiss C, Lehmann G, et al. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 2006; 65: 101-4.
51. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1013-9.
52. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsiloncarboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford) 2003; 42: 1242-6.
53. Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 2008; 26: 93-100.
54. Shiraki M, Kuroda T, Shiraki Y, Tanaka S, Higuchi T, Saito M. Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab 2011; 29: 62-70.
55. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 2380-6.
56. Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 2009; 32: 2263-8.
57. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007; 8: 1138-43.
58. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-27.
59. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-31.
60. Bucciarelli LG, Wendt T, Qu W, et al. Schmidt: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein Enull mice. Circulation 2002; 106: 2827-35.
61. Humpert PM, Djuric Z, Kopf S, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6: 9.
62. Fukami A, Adachi H, Yamagishi S, et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism 2009; 58: 1688-93.
63. Soro-Paavonen A, Watson AM, Li J, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-9.
64. Brown DL, Robbins R. Developments in the therapeutic applications of bisphosphonates. J Clin Pharmacol 1999; 39: 651-60.
65. Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999; 264: 108-111.
66. Yamagishi S, Abe R, Inagaki Y, Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165: 1865-74.
67. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30.
68. Okamoto T, Yamagishi S, Inagaki Y, et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun 2002; 297: 419-24.
69. Yamagishi S, Matsui T, Nakamura K, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 2005; 27: 189-95.
70. Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD. Opposing effects of bisphosphonates and advanced glycation endproducts on osteoblastic cells. Eur J Pharmacol 2008; 600: 140-7.
71. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009; 20: 887-94.
72. Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008; 19: 1343-54.
73. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267-94.
74. Silverman SL. New selective estrogen receptor modulators (SERMs) in development. Curr Osteoporos Rep 2010; 8: 151-3.
75. Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int 2010; 21: 655-66.
76. Pullerits R, d'Elia HF, Tarkowski A, Carlsten H. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. Rheumatology (Oxford) 2009; 48: 785-90.
77. Panuccio V, Mallamaci F, Tripepi G, et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis 2002; 40: 810-5.
78. Saito M, Marumo K, Kida Y, et al. Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent crosslinks of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos Int 2011 (in press).